Catalyst Says FDA Is Breaking Law By Approving Rival's Drug

Law360 (September 22, 2020, 5:02 PM EDT) -- Catalyst Pharmaceuticals Inc. fought Tuesday against a federal judge's determination that the U.S. Food and Drug Administration lawfully approved a lower-cost version of a drug that treats a rare autoimmune disease, arguing that the Orphan Drug Act does not allow the approval of two drugs to treat the same disease.

In a Zoom hearing before U.S. District Judge Beth Bloom, Catalyst's attorney Philip Perry told the court that U.S. Magistrate Judge Lauren Louis got it wrong when she recommended denying summary judgment to the Florida-based pharmaceutical company, which is suing the FDA over its approval of Jacobus Pharmaceutical Co. Inc.'s Ruzurgi,...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!